News coverage about McKesson (NYSE:MCK) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. McKesson earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.3223025479441 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Shares of McKesson (MCK) opened at $152.83 on Thursday. McKesson has a 12-month low of $133.82 and a 12-month high of $178.86. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.61 and a current ratio of 1.07. The firm has a market cap of $31,860.00, a price-to-earnings ratio of 6.77, a PEG ratio of 1.39 and a beta of 1.22.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Thursday, February 1st. The company reported $3.41 EPS for the quarter, topping analysts’ consensus estimates of $2.92 by $0.49. The business had revenue of $53.62 billion during the quarter, compared to analysts’ expectations of $51.98 billion. McKesson had a net margin of 2.34% and a return on equity of 22.98%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the company posted $3.04 earnings per share. research analysts anticipate that McKesson will post 12.69 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, April 2nd. Shareholders of record on Thursday, March 1st will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Wednesday, February 28th. McKesson’s payout ratio is 6.02%.

Several brokerages have issued reports on MCK. Needham & Company LLC upped their price target on shares of McKesson from $173.00 to $180.00 and gave the company a “buy” rating in a research report on Tuesday, January 23rd. Robert W. Baird reiterated a “buy” rating and set a $200.00 price objective on shares of McKesson in a research report on Wednesday, January 17th. Jefferies Group upgraded shares of McKesson from a “hold” rating to a “buy” rating and set a $205.00 price objective for the company in a research report on Wednesday, January 24th. Mizuho set a $186.00 price objective on shares of McKesson and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Credit Suisse Group reiterated a “sell” rating and set a $130.00 price objective on shares of McKesson in a research report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $178.97.

In other McKesson news, Chairman John H. Hammergren sold 65,000 shares of the firm’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $160.00, for a total value of $10,400,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect McKesson (MCK) Stock Price” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at

McKesson Company Profile

McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare.

Insider Buying and Selling by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with's FREE daily email newsletter.